Compare COSM & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | ALLR |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 19.3M |
| IPO Year | 2009 | 2021 |
| Metric | COSM | ALLR |
|---|---|---|
| Price | $0.30 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 982.5K | 191.2K |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,271,815.00 | $320,000.00 |
| Revenue This Year | $54.08 | N/A |
| Revenue Next Year | $32.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.28 | $0.77 |
| 52 Week High | $1.32 | $2.35 |
| Indicator | COSM | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 51.62 |
| Support Level | $0.29 | $1.01 |
| Resistance Level | $0.41 | $1.45 |
| Average True Range (ATR) | 0.02 | 0.13 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 7.85 | 34.69 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.